IRIS
CRISCUOLO, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 377
NA - Nord America 293
AS - Asia 133
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
SA - Sud America 1
Totale 814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 293
SE - Svezia 188
IT - Italia 107
CN - Cina 74
SG - Singapore 51
RU - Federazione Russa 46
FI - Finlandia 16
IE - Irlanda 9
DE - Germania 5
IN - India 4
AU - Australia 3
CM - Camerun 3
A1 - Anonimo 2
HK - Hong Kong 2
PL - Polonia 2
BR - Brasile 1
EU - Europa 1
FR - Francia 1
GB - Regno Unito 1
KR - Corea 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
ZA - Sudafrica 1
Totale 814
Salva come PNG Salva come JPEG
Città #
Ashburn 75
Milan 67
Princeton 39
Shanghai 39
Lawrence 38
New York 26
Singapore 25
Moscow 19
Helsinki 14
Dublin 9
Rome 7
Guangzhou 6
Boardman 5
Ancona 4
Pune 4
Shenzhen 4
South San Francisco 4
Turin 4
Washington 4
Beijing 3
Bologna 3
Busto Arsizio 3
Council Bluffs 3
Los Angeles 3
Magnago 3
Melbourne 3
Santa Clara 3
Bergamo 2
Como 2
Dallas 2
Gatchina 2
Kunming 2
Kwai Chung 2
Las Vegas 2
Seattle 2
Segrate 2
Xi'an 2
Bacoor 1
Bari 1
Bloemfontein 1
Borås 1
Espoo 1
Foshan 1
Frankfurt am Main 1
Houston 1
Jiaxing 1
Lansing 1
Lappeenranta 1
London 1
Lübeck 1
Nanjing 1
Omsk 1
Redwood City 1
Rockville 1
San Diego 1
San Francisco 1
St Petersburg 1
São Paulo 1
Taizhou 1
Vimodrone 1
Volgograd 1
Totale 461
Salva come PNG Salva come JPEG
Nome #
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects 37
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine 34
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy 30
Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19 29
Alternative methods of vaccine delivery: An overview of edible and intradermal vaccines 28
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? 26
Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge 26
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 24
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models 23
A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation 23
Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols 23
Evaluation of synergistic interactions of anti-HCV/E2 monoclonal antibodies 23
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 22
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs 22
Characterization of two human monoclonal anti-E2/HCV antibodies for potential application in prevention and treatment of HCV infection 21
Bacteriophages and Their Immunological Applications against Infectious Threats 21
Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects 21
Viral Respiratory Pathogens and Lung Injury 21
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes 21
The interferon landscape along the respiratory tract impacts the severity of COVID-19 21
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects 21
The initial interplay between HIV and mucosal innate immunity 20
Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection 20
Broadly neutralizing human monoclonal antibodies: a novel resource against influenza viruses 20
Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021 20
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials 19
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II 18
HUMAN MONOCLONAL ANTIBODY ENDOWED WITH ANTI-HSV-1 AND -2 ACTIVITY STRONGLY INHIBITS VIRUS REPLICATION 18
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion? 18
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2 17
Characterization of a lineage c.36 sars-cov-2 isolate with reduced susceptibility to neutralization circulating in lombardy, italy 17
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection 17
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines 16
Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis 16
IN VIVO PROTECTION CONFERRED BY HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST HSV-1 AND 2 16
Phage Therapy: An Alternative to Antibiotics 15
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro 15
Molecular characterization of the human neutralizing response against hepatitis C virus and its role in the prediction of the infection outcome 15
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases 14
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. 14
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle 14
Role and potential therapeutic use of antibodies against herpetic infections 14
Next Generation Vaccines for Infectious Diseases 14
Synergistic neutralization of HCV by two broadly neutralizing human monoclonal antibodies 14
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19 12
A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells 11
Editorial: Viral escape of mucosal immunity in sexually transmitted diseases 8
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome 7
Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity 7
null 1
Totale 944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.602
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 6 0 0 0 0 1
2020/202113 2 0 0 2 4 0 2 0 0 3 0 0
2021/202284 6 3 10 10 13 7 9 2 2 9 0 13
2022/2023356 89 78 49 7 3 41 33 30 15 2 8 1
2023/2024315 1 20 42 62 19 62 9 25 13 8 18 36
2024/2025121 81 20 13 7 0 0 0 0 0 0 0 0
Totale 944